Calendar
Prev MonthPrev Month Next MonthNext Month
IEC at SID 2021 - Virtual Meeting
Thursday, May 06, 2021
Category: IEC Events (for everyone)

BIOMARKERS IEC VIRTUAL SYMPOSIUM AT THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY 2021

This symposium will take during the 2021 Virtual Society for Investigative Dermatology.    

Watch On-Demand Webcast

PROGRAM CHAIRS

  • Emma Guttman, MD PhD, New York, NY, USA
  • Dirkjan Hijnen, MD PhD, Rotterdam, Netherlands
  • Kenji Kabashima, MD PhD, Kyoto, Japan

AGENDA

Welcome & Program Overview
Emma Guttman

Cytokines and chemokines as a possible biomarker in atopic dermatitis
Kenji Kabashima MD PhD | Kyoto, Japan
Professor, Department of Dermatology
Kyoto University Graduate School of Medicine

Atopic Dermatitis 3.0: from clinical phenotypes to biomarker based endophenotypes
DirkJan Hijnen, MD PhD | Rotterdam, Netherlands Associate Professor
Dept of Dermatology, Erasmus University Medical Center

Treatment response biomarkers and minimally invasive skin biomarkers
Emma Guttman, MD, PhD | New York, NY
Waldman Professor and System Chair, Dermatology and Immunology
Director, Center of Excellence for Eczema and the Occupational Dermatitis Clinic
Director, Laboratory for Inflammatory Skin Diseases
Icahn School of Medicine at Mount Sinai

Fireside Chat Panel Discussion & Closing Remarks
Emma Guttman | DirkJan Hijnen | Kenji Kabashima

 


FACULTY

Emma Guttmann, MD PhD, IEC Immediate Past President is the Waldman Professor and System Chair, Dermatology and Immunology, and the director of both the Center of Excellence for Eczema and the Occupational Dermatitis Clinic and Laboratory for Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York. Guttman’s major focus is atopic dermatitis (AD).

She has:

  • made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology and opening the door to new therapeutics
  • developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease
  • established the reversibility of the AD phenotype
  • defined a series of biomarkers that are now accelerating testing of novel pathway-specific drugs for AD.

She earned her doctor of medicine degree from Sackler in Tel-Aviv, Israel, and a doctor of philosophy degree from Bar-Ilan University in Israel. After receiving her board certification in dermatology in Israel, Guttman moved to the United States to pursue a postdoctoral fellowship at The Rockefeller University in New York, NY, and a second dermatology residency at Weill Cornell Medicine in New York, NY.

In addition to serving as president and co-founder of the International Eczema Council (IEC), Guttman was elected to the American Society for Clinical Investigation (ASCI)


Kenji Kabashima, MD PhD is incoming IEC Secretary as well as chair and professor of the Department of Dermatology at Kyoto University Graduate School of Medicine in Japan, a principal investigator at the Institute of Medical Biology (IMB/SIgN) in Singapore, and visiting consultant at the National Skin Centre in Singapore. His main interests include the mechanism of inflammatory skin diseases and three-dimensional visualization of the skin using two-photon microscopy.

Kabashima graduated from Kyoto University in 1996 and was trained in medicine/dermatology at the United States Naval Hospital Yokosuka Japan, Kyoto University Hospital, and University of Washington Medical Center. He started research on bioactive lipid mediators at Kyoto University, which led to his PhD. Then, he studied at the Department of Dermatology, Kyoto University Graduate School of Medicine; University of California, San Francisco; and University of Occupational and Environmental Health.


DirkJan Hijnen, MD PhD is a dermatologist, instructor, and researcher at the Erasmus MC in Rotterdam, the Netherlands. He leads the outpatient clinic for patients with atopic dermatitis. His research focuses on the development of new tools for the characterization of atopic dermatitis patients. He believes the integration of clinical, serological, cellular, and molecular biomarkers will lead to a better understanding of disease mechanisms and contribute to precision medicine.

Hijnen earned an MSc degree in medical biology from the University of Amsterdam and an MD and PhD from from the University of Utrecht, where he studied the role of T cells in the pathogenesis of atopic dermatitis. During his dermatology residency, Hijnen received a grant to continue his T-cell research in Rachael A. Clark’s lab at the Brigham and Women’s Hospital in Boston, MA, USA. From 2011 to 2017, he worked at the University Medical Center of Utrecht.